title: Botulinum Toxin for the Management of Sjögren Syndrome-Associated Recurrent Parotitis.
abstract: Recurrent parotitis is a rare manifestation of Sjögren syndrome. The management of recurrent parotitis is challenging because conservative methods may be of limited efficacy and invasive approaches carry the risk of complications. Botulinum toxin has been shown to reduce salivary flow, and consequently, the results of its use in the management of recurrent parotitis have been encouraging. A 65-year-old female patient with recurrent parotitis due to Sjögren syndrome was referred to us, complaining of weekly bouts of inflammation. She required a course of antibiotics monthly to control bacterial superinfections. We treated her with onabotulinumtoxinA injections into both parotid glands at regular intervals. After her second injection cycle, she denied further inflammatory bouts, has not required antibiotics in more than 36 months, and denied any side effects. Botulinum toxin may be a safe and effective method of treating Sjögren syndrome-associated recurrent parotitis.
authors.affiliation: Resident, Department of Surgery, Blacktown Hospital, Sydney, New South Wales, Australia. Electronic address: lm.oneil3@gmail.com.
authors.forename: Luke M
authors.initials: LM
authors.lastname: O'Neil
authors.affiliation: Associate Professor and Otorhinolaryngologist, Department of Otolaryngology, Head and Neck Surgery, Crown Princess Mary Cancer Care Centre, and Sydney Medical School, Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia.
authors.forename: Carsten E
authors.initials: CE
authors.lastname: Palme
authors.affiliation: Otorhinolaryngologist, Department of Otolaryngology, Head and Neck Surgery, Crown Princess Mary Cancer Care Centre, and Sydney Medical School, Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia.
authors.forename: Faruque
authors.initials: F
authors.lastname: Riffat
authors.affiliation: Neurologist, Sydney Medical School and Department of Neurology, Westmead Hospital, Sydney, New South Wales, Australia.
authors.forename: Neil
authors.initials: N
authors.lastname: Mahant
mesh_terms: D000368:Aged; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D010309:Parotitis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D012008:Recurrence; D012859:Sjogren's Syndrome / Q000150:complications*
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A